Rx00077 - Cytarabine


Name:
Cytarabine
Rx ID:
Rx00077
Validation Level:
Phenomic Similarity:
0.545
Reference ID:
DB00987
Primary Indications:
Acute non-lymphocytic leukemia; acute lymphocytic leukemia; blast phase of chronic myelocytic leukemia
Orphan Indications:
No annotated orphan indications.
Rare Indications:
Glimoa
Common Indications:
Lymphomatous meningitis; adult acute non-lymphocytic leukemi; juvenile acute non-lymphocytic leukemi; acute lymphocytic leukemia; chronic myelocytic leukemia
Drug Interactions:
Digoxin Trastuzumab;
Food Interactions:
No annotated food interactions in DrugBank.

Interactive 3D Model

Interactive Drug Target Network

Interactive Bipartite Drug Repurposing Graph

Rx00077
Primary Indication
Secondary Indication

Visualize Chemical Properties

Select x-axis

Select y-axis

Disease prevalence from Electronic Health Records

Click row to show all

Disease A Disease B A∩B A∩¬B B∩¬A Odds-Ratio P-Value Adjusted P-Value
acute non-lymphocytic leukemia leukemia 280 941 709 1693.392 0 0.0
acute lymphocytic leukemia leukemia 280 1823 709 874.099 0 0.0
blast phase of chronic myelocytic leukemia acute lymphocytic leukemia 85 433 1823 434.49 3.32E-185 1.07e-181

Shared Genetic Architectures of Disease Pairs

Click row to show all

Disease A Disease B Adjusted P-Value Shared Gene IDs
ACUTE NON-LYMPHOCYTIC LEUKEMIA ACUTE LYMPHOCYTIC LEUKEMIA 1.43e-196 3807, ABCB1, ABCC1, ABCC2, ABCC3, ABCG2, ABHD16A, ABL1, ACAA1, ACAD11, ADAM19, ADAP1, AKR1C3, AKT1, ALOX12, ALOX12B, ALOX15, ALOX15B, ALOX5, ALOX5AP, ALOXE3, APAF1, APEX1, APOA2, ARHGAP26, ARID5B, ASXL1, ATG9B, ATM, BAK1, BAX, BCL2, BCL2L11, BPI, BRAF, BRCA2, BRD7, C1D, C1QA, C1QB, C1QBP, C1QC, C1RL, C1S, C2, C3, C4BPA, C4BPB, C5, C5AR1, C6, C7, C8A, C8B, C8G, C9, CASP8, CBL, CCL1, CCL11, CCL13, CCL18, CCL2, CCL20, CCL24, CCL26, CCL5, CCL7, CCL8, CCR1, CCR3, CCR4, CCR6, CCR7, CCR8, CCR9, CD14, CD180, CD209, CD46, CD55, CD93, CDA, CDKN1A, CDKN2A, CDKN2B, CDKN2B-AS1, CEBPA, CEBPE, CFB, CLCA1, CLCA2, CNTNAP1, CORO1C, CRP, CTLA4, CTNNB1, CXCL10, CXCL12, CXCR1, CXCR2, CYBA, CYP1A1, CYP1B1, CYP21A2, CYP2B6, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5, DAB2, DCK, DDR1, DEF6, DEFA3, DEFA4, DEFA5, DEFA6, DEFB1, DEFB118, DEFB119, DEFB126, DEFB127, DHFR, DHX33, DLG5, DNMT3A, DOK2, EPHX1, EPO, ERCC1, ERCC2, ESR1, ETV6, F5, FAS, FASLG, FCER1A, FCER1G, FCER2, FCGR2A, FCGRT, FGF2, FLJ90680, FLT3, FOXJ2, GGCT, GLS, GPR108, GPR44, GSTM1, GSTO2, GSTP1, GSTT1, HES7, HFE, HGF, HLA-A, HLA-B, HLA-C, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-G, HSPA6, ICAM1, ICAM2, ICAM3, ICAM4, ICAM5, IDH1, IDH2, IKZF1, IL10, IL11RA, IL17C, IL1RN, IL4, IL6, IL8, INSL3, IRAK2, IRAK3, IRAK4, IRF8, ITGB2, JAK1, JAK2, JAK3, KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR2DP1, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5, KIR3DL1, KIR3DL2, KIR3DL3, KIR3DP1, KIR3DS1, KIT, KLK1, KLK15, KLK2, KLK4, KLK6, KLK7, KLKB1, KRAS, LBP, LMAN1, LPO, LTA, LTBR, LY6G6D, LY96, MAL, MASP1, MASP2, MBL2, MBP, MDM2, MEFV, MGMT, MIF, MLH1, MLL, MPO, MTAP, MTHFR, MTR, MUC6, MUC7, MYD88, NAB2, NAT1, NAT2, NBN, NCF2, NCF4, NDUFS2, NF1, NF2, NFKB1, NIPAL4, NOD1, NOD2, NOS1, NOS2, NOS3, NOTCH1, NQO1, NRAS, NUDT6, OR10J3, PARP1, PDCD10, PFKFB2, PHF6, PIM1, PML, PTGDR, PTGS2, PTPN11, RAC1, RAC2, RAD51, RASA1, RAVER1, RPS4XP13, RUNX1, SCAF4, SCGB1A1, SCNN1A, SECTM1, SELE, SELP, SELPLG, SENP3, SERPINB2, SERPINB3, SERPINC1, SERPINE1, SERPING1, SERPINI1, SHMT1, SLC22A2, SLC2A11, SLCO1A2, SLCO1B1, SLCO1B3, SOCS1, SOCS2, SOCS3, SOCS4, SOD1, SOD2, SOD3, SPI1, STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, STAT6, STK19, TERC, TERT, TET2, TGFB1, TICAM1, TLR1, TLR10, TLR2, TLR3, TLR4, TLR6, TLR9, TLX1, TMCO6, TNF, TNFRSF18, TNFRSF1B, TNFSF18, TNFSF9, TOLLIP, TOP2A, TP53, TPMT, TRAM1, TSLP, TWF1, TWF2, TYK2, TYMS, UGT1A1, VCAM1, VDR, VEGFA, WDHD1, WT1, XDH, XIAP, XPA, XPC, XRCC1, XRCC3, XRCC4, ZNF76, ZP1
ACUTE LYMPHOCYTIC LEUKEMIA GLIOMA 2.57e-145 ABCB1, ABCG2, ABHD16A, ACAA1, ACAD11, ADAM19, ADAM33, ADAP1, AKT1, ALOX12, ALOX12B, ALOX15, ALOX15B, ALOX5, ALOX5AP, ALOXE3, APEX1, APOA2, ATG9B, ATM, BCL2, BPI, BRAF, BRCA2, C1D, C1QA, C1QB, C1QBP, C1QC, C1RL, C1S, C2, C3, C4BPA, C4BPB, C5, C5AR1, C6, C7, C8A, C8B, C8G, C9, CASP8, CAT, CCDC26, CCL1, CCL11, CCL13, CCL18, CCL2, CCL20, CCL24, CCL26, CCL5, CCL7, CCL8, CCND1, CCR1, CCR3, CCR4, CCR6, CCR7, CCR8, CCR9, CD14, CD180, CD209, CD46, CD55, CD93, CDK4, CDKN1A, CDKN2A, CDKN2B, CDKN2B-AS1, CFB, CLCA1, CLCA2, CNTNAP1, CORO1C, CRP, CTLA4, CTNNB1, CXCR1, CXCR2, CYBA, CYP1A1, CYP1B1, CYP21A2, CYP2E1, DAB2, DAXX, DEF6, DEFA3, DEFA4, DEFA5, DEFA6, DEFB1, DEFB118, DEFB119, DEFB126, DEFB127, DHX33, DLG5, EPHX1, ERCC1, ERCC2, ERCC4, F5, FAS, FASLG, FCER1A, FCER1G, FCER2, FCGR2A, FCGRT, FGF2, FLJ90680, FLT3, FOXJ2, GGCT, GLS, GPR108, GPR44, GSTM1, GSTM3, GSTP1, GSTT1, HES7, HGF, HLA-A, HLA-B, HLA-C, HLA-DQB1, HLA-DRB1, HLA-DRB3, HRAS, HSPA6, ICAM1, ICAM2, ICAM3, ICAM4, ICAM5, IDH1, IDH2, IGF1, IGF1R, IGF2, IGF2R, IL10, IL11RA, IL12A, IL12B, IL16, IL17C, IL4, IL4R, IL6, IL8, INSL3, IRAK2, IRAK3, IRAK4, ITGB2, JAK2, JAK3, KIT, KLK1, KLK15, KLK2, KLK4, KLK6, KLK7, KLKB1, KRAS, LBP, LMAN1, LPO, LRP5, LTBR, LY6G6D, LY96, MAL, MASP1, MASP2, MBL2, MBP, MDM2, MEFV, MGMT, MIF, MIR146A, MIR196A2, MLH1, MMP7, MPO, MSH6, MTHFR, MTR, MTRR, MUC6, MUC7, MUTYH, MYD88, NAB2, NAT2, NBN, NCF2, NCF4, NDUFS2, NF1, NFKB1, NFKBIA, NIPAL4, NOD1, NOD2, NOS1, NOS2, NOS3, NQO1, NUDT6, OGG1, OR10J3, PARP1, PDCD10, PFKFB2, PIK3CA, PON1, PTEN, PTGDR, PTGS2, PTPN11, RAC1, RAC2, RAD51, RAG1, RAVER1, RPS4XP13, SCAF4, SCGB1A1, SCNN1A, SECTM1, SELE, SELP, SELPLG, SENP3, SERPINB2, SERPINB3, SERPINC1, SERPINE1, SERPING1, SERPINI1, SLC2A11, SOCS1, SOCS2, SOCS3, SOCS4, SOD1, SOD2, SOD3, STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, STAT6, STK19, SYK, TERC, TERT, TICAM1, TLR1, TLR10, TLR2, TLR3, TLR4, TLR6, TLR9, TMCO6, TNFRSF18, TNFSF18, TNFSF9, TOLLIP, TP53, TRAM1, TSLP, TWF1, TWF2, TYK2, TYMS, UGT1A1, VCAM1, VDR, VEGFA, WDHD1, WWOX, XDH, XPC, XRCC1, XRCC3, XRCC4, ZNF76, ZP1

Chemical, Pharmacological and Biological Annotations


ATC Code:
L01BC01
Brands:
Ara-C (Gobbi); Cytosar-U (Pfizer)
Categories:
Antiviral Agents; Immunosuppressive Agents; Antimetabolites, Antineoplastic
ChEBI ID:
28680
PubChem ID:
6253
KEGG Drug ID:
D00168
SMILE:
NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
InChI:
1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1
Classification:
Kingdom:
Organic Compounds
Superclass:
Organooxygen Compounds
Class:
Carbohydrates and Carbohydrate Conjugates
Subclass:
Glycosyl Compounds
Indication:
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Pharmacodynamics:
Cytarabine is an antineoplastic anti-metabolite used in the treatment of several forms of leukemia including acute myelogenous leukemia and meningeal leukemia. Anti-metabolites masquerade as purine or pyrimidine - which become the building ...
Click to show more...
Description:
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific ...
Click to show more...
Mechanism:
Cytarabine acts through direct DNA damage and incorporation into DNA. Cytarabine is cytotoxic to a wide variety of proliferating mammalian cells in culture. It exhibits cell phase specificity, primarily killing cells undergoing DNA synthesi...
Click to show more...

Adsorption, Distribution, Metabolism, Excretion and Toxicity


Human Intestinal Absorption:
+
Blood Brain Barrier:
+
Caco-2 permeable:
-
P-glycoprotein substrate:
Non-substrate
P-glycoprotein inhibitor I:
Non-inhibitor
P-glycoprotein inhibitor II:
Non-inhibitor
Renal organic cation transporter:
Non-inhibitor
CYP450 2C9 substrate:
Non-inhibitor
CYP450 2D6 substrate:
Non-inhibitor
CYP450 2C19 substrate:
Non-inhibitor
CYP450 inhibitory promiscuity:
Low CYP Inhibitory Promiscuity
Ames test:
Non AMES toxic
Carcinogenicity:
Non-carcinogens
Biodegradation:
Not ready biodegradable
Rat acute toxicity:
1.7184 LD50, mol/kg
hERG inhibition (predictor I):
Weak inhibitor
hERG inhibition (predictor II):
Non-inhibitor

Contact Us:
Please contact us if you have questions or comments about RepurposeDB. You can also contact us if you need help in submitting your drug repositioning investigation to RepurposeDB.


Dudley Laboratory
Department of Genetics and Genomic Sciences
Icahn Institute for Genomics and Multiscale Biology
Icahn School of Medicine at Mount Sinai
One Gustave L. Levy Place, Box 1498
Manhattan, New York City, NY
repurposedb@dudleylab.org